Dotarem vs Gadobutrol Contrast for Breast MRI

Launched by UNIVERSITY OF MASSACHUSETTS, WORCESTER · Nov 1, 2018

Keywords

ClinConnect Summary

This clinical trial is studying two types of contrast agents used during breast MRI scans: Dotarem and Gadobutrol (Gadavist). The goal is to see if Dotarem works just as well as Gadavist in helping doctors identify breast lesions, which can be important for diagnosing conditions like breast cancer. Women who are 18 years or older and are scheduled for a breast MRI with contrast may be eligible to participate. To join, participants should have had, or be likely to have, a breast tissue sample taken recently, with results available within six months.

If you choose to participate, you will be randomly assigned to receive either Dotarem or Gadavist during your MRI. The trial will look at the quality of the images and how helpful they are for diagnosis. It's important to note that pregnant women, those who have started treatment for breast cancer, and premenopausal women outside a specific time frame in their menstrual cycle cannot participate. This study is currently recruiting participants, and your involvement could help improve breast imaging techniques in the future.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Females age 18 and older
• • Scheduled to undergo a clinically indicated MRI of the breast with contrast.
• • Have undergone, are scheduled to undergo, or are likely to be scheduled to undergo a breast tissue sampling exam with histology results available within 6 months of their MRI.
• Exclusion Criteria:
• • Pregnant
• • Have already begun therapeutic treatment for breast cancer including surgery (lumpectomy or mastectomy), radiotherapy, or chemotherapy.
• • Pre Menopause women outside of the 7-14 days from cycle